Nerve-Calming amino acid may cut heart risk in kidney disease
NCT ID NCT03982160
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates whether a single infusion of L-arginine, an amino acid, can reduce abnormally high sympathetic nerve activity in people with chronic kidney disease (CKD). High nerve activity is linked to increased cardiovascular risk in CKD patients. Researchers will measure nerve signals in the leg before and after the infusion to see if L-arginine helps lower this activity. The study involves 15 adults aged 35 to 75 with moderate CKD.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
L-Arginine
What this could lead to
If successful, this could point toward a new way to lower cardiovascular risk in chronic kidney disease patients by calming an overactive nervous system.
What could go wrong
This is a small, early-phase study with only 15 participants, so results may not apply to all patients. The intervention is a single infusion, not a long-term treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UT Southwestern
Dallas, Texas, 75390, United States
-
University of Delaware
Newark, Delaware, 19716, United States